CN110403933A - 二氢青蒿素衍生物在制备抗肿瘤药物中的应用 - Google Patents
二氢青蒿素衍生物在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN110403933A CN110403933A CN201910786538.2A CN201910786538A CN110403933A CN 110403933 A CN110403933 A CN 110403933A CN 201910786538 A CN201910786538 A CN 201910786538A CN 110403933 A CN110403933 A CN 110403933A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- nmr
- cdcl
- independently
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 title claims abstract description 16
- 229960002521 artenimol Drugs 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 8
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 8
- -1 amino, hydroxyl Chemical group 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- 101710113436 GTPase KRas Proteins 0.000 claims description 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 14
- 230000001665 lethal effect Effects 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 231100000518 lethal Toxicity 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000001924 fatty-acyl group Chemical group 0.000 claims 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 190
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 80
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 45
- 238000004896 high resolution mass spectrometry Methods 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 241001597008 Nomeidae Species 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229930101531 artemisinin Natural products 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 229930183339 qinghaosu Natural products 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- JAAIPIWKKXCNOC-UHFFFAOYSA-N 1h-tetrazol-1-ium-5-thiolate Chemical compound SC1=NN=NN1 JAAIPIWKKXCNOC-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- ZPOLNCDBPYJDSE-UHFFFAOYSA-N 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid Chemical compound O=CNC(C(=O)O)CC1=CC=C(N(CCCl)CCCl)C=C1 ZPOLNCDBPYJDSE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- WZUUZPAYWFIBDF-UHFFFAOYSA-N 5-amino-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound NC1=NNC(S)=N1 WZUUZPAYWFIBDF-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N 5-methyl-2h-tetrazole Chemical compound CC=1N=NNN=1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了式I所示的二氢青蒿素衍生物在制备抗肿瘤药物中的应用，拓宽了二氢青蒿素衍生物的制药用途。
Description
技术领域
本发明属于化合物的医药用途技术领域，涉及一类二氢青蒿素衍生物在制备抗肿瘤药物中的应用。
背景技术
青蒿素及其衍生物具有高效、快速和低毒的抗疟活性，在全世界范围内得到广泛应用。近年来研究表明，青蒿素及其衍生物还具有抗炎、抗细菌脓毒症、抗组织纤维化和抗肿瘤等多种生物活性。目前对青蒿素的研究主要集中在提高活性、拓宽药效、增加稳定性和溶解性等方面。发明人所在课题组在过去的研究中，将一些活性小分子或药物引入到二氢青蒿素结构中，设计了多种结构类型的二氢青蒿素衍生物，通过条件的探索，简易、高收率地实现了这些目标化合物的合成，并发现其中部分化合物虽然本身不具备抗菌作用，但其可以作为β-内酰胺类抗生素的抗菌增效剂。
合成致死(Synthetic lethality)是指2个非致死性基因同时突变引发死亡的一种基因互作现象。肿瘤细胞区别于正常细胞的一个重要特征是存在肿瘤相关基因的突变，寻找与肿瘤相关基因存在合成致死关系的基因并以此为靶标研发药物，干扰其活性，理论上能够高选择性地杀灭肿瘤细胞，为肿瘤治疗提供新的突破口。K-ras是一种原癌基因，长约35kb，位于12号染色体，是RAS基因家族成员之一，编码K-ras蛋白。K-ras蛋白具有分子开关作用，在很多信号通路中发挥重要作用。研究表明，体细胞K-ras基因突变与多种人类恶性肿瘤如肺癌、白血病、黏蛋白腺癌、胰腺癌、结直肠癌等有关，而生殖细胞K-ras基因突变与努南综合征和心脏-面部-皮肤(cardio-facio-cutaneous)综合征相关。Wnt信号通路激活是K-ras突变细胞的存活所必需的。
发明内容
本发明的目的在于考察二氢青蒿素衍生物在抗肿瘤方面的活性，以拓宽二氢青蒿素衍生物的制药用途。
经研究，本发明提供如下技术方案：
式I所示的二氢青蒿素衍生物或其消旋体、立体异构体、互变异构体、氮氧化物、药学上可接受的盐在制备抗肿瘤药物中的应用：
式I中，n为1或2；
Y为-NR1R2、
R1和R2独立地为H、C1-C3烷基或C1-C3羟烷基；
R3为H、C1-C3烷基、C1-C3羟烷基、取代或未取代苯基、叔丁氧羰基、苄氧羰基或脂肪酰基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C3烷基；
R4和R5独立地为H或C1-C3烷基；
R6和R7独立地为H、氨基、羟基或C1-C3烷基；
R8为H、C1-C3烷基、C1-C3烷硫基、取代或未取代苯基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C3烷基。
进一步，式I中，
R1和R2独立地为H、C1-C2烷基或C1-C2羟烷基；
R3为H、C1-C2烷基、C1-C2羟烷基、取代或未取代苯基、叔丁氧羰基、苄氧羰基或烷酰基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C2烷基；
R4和R5独立地为H或C1-C2烷基；
R6和R7独立地为H、氨基、羟基或C1-C2烷基；
R8为H、C1-C2烷基、C1-C2烷硫基、取代或未取代苯基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C2烷基。
进一步，式I中，
R1和R2独立地为H、C1-C2烷基或C1-C2羟烷基；
R3为H、C1-C2烷基、C1-C2羟烷基、苯基、叔丁氧羰基、苄氧羰基或乙酰基；
R4和R5独立地为H或C1-C2烷基；
R6和R7独立地为H、氨基、羟基或C1-C2烷基；
R8为H、C1-C2烷基、C1-C2烷硫基或苯基。
进一步，式I中，
R1和R2独立地为H、甲基、乙基或羟乙基；
R3为H、甲基、羟乙基、苯基或叔丁氧羰基；
R4和R5独立地为H或甲基；
R6和R7独立地为H或氨基；
R8为H、甲基、甲硫基或苯基。
进一步，式I所示的二氢青蒿素衍生物为以下化合物中的任一种：
进一步，式I所示的二氢青蒿素衍生物为以下化合物中的任一种：2a-5,2b-4,2b-5,4b-6,4b-8,5b-6。
进一步，所述抗肿瘤药物为具有K-ras/Wnt合成致死活性的药物。
进一步，所述肿瘤为结直肠癌。
除另有说明外，本发明中的术语“消旋体”是指由等量对映体构成的光学不活性的有机物。“立体异构体”是指原子组成及键接相同而原子在三维空间排列上不同的分子。“互变异构体”是指因分子中某一原子在两个位置迅速移动而产生的官能团异构体。“氮氧化物”是指三级氮连接氧原子形成+N-O-结构单元的有机物。“药学上可接受的盐”可以是酸性盐，也可以是碱性盐，例如无机酸盐、有机酸盐、无机碱盐或有机碱盐。
本发明的有益效果在于：本发明公开了式I所示的二氢青蒿素衍生物在制备抗肿瘤药物中的应用，拓宽了二氢青蒿素衍生物的制药用途。
具体实施方式
为了使本发明的目的、技术方案和有益效果更加清楚，下面将对本发明的优选实施例进行详细的描述。
优选实施例中使用的主要试剂及规格:二甲胺、二乙胺、乙醇胺、氮甲基乙醇胺、二乙醇胺、吡咯烷、哌啶、吗啉、乙腈、二氯甲烷(重庆化学试剂总厂,AR)；二氢青蒿素(重庆华立武陵山制药有限公司,AR)；溴乙醇(上海达瑞精细化工有限公司,AR)；无水哌嗪、N-甲基哌嗪、N-羟乙基哌嗪、N-Boc-哌嗪、N-苯基哌嗪、3-溴-1-丙醇、咪唑、2-甲基咪唑、4-甲基咪唑、吡唑、3,5-二甲基吡唑、苯并咪唑、1,2,3-三氮唑、1,2,4-三氮唑、苯并三氮唑、3-氨基-1,2,4-三氮唑、3-氨基-5-巯基-1,2,4-三氮唑、1-H-四氮唑、5-甲基四氮唑、5-苯基四氮唑、5-甲巯基四氮唑(上海达瑞精细化工有限公司,＞98％)；1-羟基-苯并三氮唑(上海共价化学科技公司,工业级)；46.5％BF3.Et2O(上海晶纯试剂有限公司,AR)；其余试剂均为市售化学纯或分析纯产品,未经纯化直接使用。
优选实施例中使用的主要仪器及型号:精密显微熔点测定仪(X-6,北京福凯仪器有限公司)；数字式自动旋光仪(WZZ-2S,上海精密科学仪器有限公司)；超导核磁共振波谱仪(AV-300,Bruker,瑞士)；高分辨质谱仪(HR ESI MS)(Varian7.0T,Varian,USA)。
实施例1、DHA胺类衍生物的合成
1、DHA脂肪胺类衍生物1的合成
DHA脂肪胺类衍生物1a-1h按照文献(Chong Wu,et al.Design,Synthesis andEvaluation of the Antibacterial Enhancement Activities of AminoDihydroartemisinin Derivatives.Molecules,2013,18,6866-6882)中所述化合物4a-4u的制备方法进行制备。
2、DHA哌嗪类衍生物2的合成
1)中间体M1的合成
中间体M1按照中国专利104418864B(双氢青蒿素与喹诺酮类化合物的偶联物及其制备方法和应用)中所述中间体IM1和IM2的制备方法进行制备。
2)DHA哌嗪类衍生物2a-1～2a-5及2b-1～2b-5的合成
在100mL圆底烧瓶中依次加入M1、CH3CN、K2CO3及哌嗪或取代哌嗪,控温搅拌反应,TLC监测反应进程。反应结束后,加入CH2Cl2 15mL和饱和NaCl水溶液20mL,静置分层,水层用CH2Cl2(10mL×2)萃取,合并有机相,饱和食盐水20mL洗涤,无水Na2SO4干燥,减压旋蒸除去CH2Cl2得粗品或纯品,必要时柱层析,干燥,即得目标化合物2。具体合成条件及结果见表1。
表1目标化合物2的合成条件及结果
目标化合物2表征数据如下:
2a-1:1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝6.6Hz,H-14),1.43(3H,s,H-15),1.22-2.06(10H,m,H-2,H-3,H-7～H-10),2.37-2.60(12H,m,H-1,H-11,H-17～H-19),3.52-3.59(1H,m,H-16),3.91-3.98(1H,m,H-16),4.80(1H,s,H-12),5.45(1H,s,H-5).
2a-2:1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.5Hz,H-13),0.96(3H,d,J＝6.6Hz,H-14),1.43(3H,s,H-15),1.46(9H,s,H-22),1.22-2.06(10H,m,H-2,H-3,H-7～H-10),2.30(3H,s,H-20),2.37-2.60(12H,m,H-1,H-11,H-17～H-19),3.52-3.59(1H,m,H-16),3.91-3.98(1H,m,H-16),4.80(1H,s,H-12),5.45(1H,s,H-5).
2a-3:黄色油状物；(c 2.5mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.3Hz,H-13),0.95(3H,d,J＝6.0Hz,H-14),1.42(3H,s,H-15),1.15-2.06(10H,m,H-2,H-3,H-7～H-10),2.28-2.59(14H,m,H-1,H-11,H-17～H-20),3.36-4.43(1H,m,H-16),3.62(2H,t,J＝5.3Hz,H-21),3.84-3.91(1H,m,H-16),4.77(1H,d,J＝3.3Hz,H-12),5.30(1H,s,H-22),5.38(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:103.98(C-4),101.90(C-12),87.84(C-5),81.07(C-6),68.54(C-16),59.36(C-22),57.72(C-20),55.52(C-17),53.26(C-19),52.45(C-1),46.76(C-18),44.31(C-7),37.39(C-11),36.32(C-10),34.57(C-3),30.76(C-9),26.12(C-8),24.63(C-15),24.30(C-2),20.29(C-14),13.01(C-13).HRMS:C23H40N2O6[M+H]+计算值441.2959,测定值441.2954.
2a-4:m.p.:107.8-109.1℃；(c 1.0mg/mL,CH2Cl2).1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.2Hz,H-13),0.96(3H,d,J＝6.0Hz,H-14),1.43(3H,s,H-15),1.46(9H,s,H-22),1.22-2.06(10H,m,H-2,H-3,H-7～H-10),2.32-2.65(8H,m,H-1,H-11,H-17 and H-18),3.40-3.44(4H,m,H-19),3.52-3.58(1H,m,H-16),3.92-4.00(1H,m,H-16),4.80(1H,s,H-12),5.46(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.6(C-21),104.0(C-4),101.9(C-12),87.8(C-5),81.0(C-6),79.7(C-22),66.0(C-16),57.9(C-17),53.5(C-19),52.0(C-1),49.2(C-18),44.4(C-7),37.4(C-11),36.4(C-10),34.6(C-3),30.8(C-9),28.4(C-23),26.4(C-17),26.1(C-8),24.6(C-15),24.4(C-2),20.4(C-14),13.0(C-13).HR MS:C27H40N2O5[M+H]+计算值497.3221,测定值497.3222.
2a-5:m.p.:90.0-91.7℃；(c 1.0mg/mL,CH2Cl2).1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.2Hz,H-13),0.95(3H,d,J＝6.0Hz,H-14),1.44(3H,s,H-15),1.23-2.06(10H,m,H-2,H-3,H-7～H-10),2.32-2.42(1H,m,H-1),2.59-2.70(7H,m,H-11,H-17 and H-18),3.21(4H,t,J＝7.5Hz,H-19),3.58-3.65(1H,m,H-16),3.98-4.05(1H,m,H-16),4.83(1H,d,J＝2.7Hz,H-12),5.48(1H,s,H-5),6.89(1H,t,J＝7.2Hz,H-23),6.94(2H,d,J＝7.8Hz,H-21),7.25-7.30(2H,m,H-22)；13C NMR(75MHz,CDCl3)δ:151.3(C-20),129.1(C-22),120.0(C-23),116.0(C-21),104.0(C-4),102.0(C-12),87.9(C-5),81.1(C-6),66.0(C-16),57.9(C-17),53.5(C-19),52.6(C-1),49.2(C-18),44.4(C-7),37.5(C-11),36.4(C-10),34.7(C-3),30.9(C-9),26.2(C-8),24.7(C-15),24.4(C-2),20.3(C-14),13.1(C-13).HR MS:C27H40N2O5(M+H)+计算值473.3010,测定值473.3014.2b-1:黄色油状物；(c 2.5mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.2Hz,H-13),0.96(3H,d,J＝6.0Hz,H-14),1.44(3H,s,H-15),1.26-2.06(12H,m,H-2,H-3,H-7～H-10and H-17),2.37-2.62(12H,m,H-1,H-11,H-18～H-20),3.37-3.44(1H,m,H-16),3.84-3.92(1H,m,H-16),4.77(1H,s,H-12),5.39(1H,s,H-5).
2b-2:黄色油状物；(c 1.2mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.2Hz,H-13),0.96(3H,d,J＝6.0Hz,H-14),1.44(3H,s,H-15),1.26-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.30(3H,s,H-20),2.37-2.62(12H,m,H-1,H-11,H-18～H-20),3.37-3.44(1H,m,H-16),3.84-3.92(1H,m,H-16),4.77(1H,s,H-12),5.39(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.1(C-4),101.9(C-12),87.8(C-5),81.0(C-6),66.5(C-16),55.5(C-18),55.0(C-19),53.1(C-20),52.5(C-21),46.0(C-1),44.4(C-7),37.1(C-11),36.4(C-10),34.6(C-3),30.9(C-9),27.0(C-17),26.2(C-8),24.6(C-15),24.4(C-2),20.3(C-14),13.0(C-13).HR MS:C23H40N2O5[M+H]+计算值425.3010,测定值425.3010.
2b-3:黄色油状物；(c 2.5mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.3Hz,H-13),0.95(3H,d,J＝6.0Hz,H-14),1.42(3H,s,H-15),1.15-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.28-2.59(14H,m,H-1,H-11,H-17～H-20),3.36-3.43(1H,m,H-16),3.62(2H,t,J＝5.3Hz,H-21),3.84-3.91(1H,m,H-16),4.77(1H,d,J＝3.3Hz,H-12),5.30(1H,s,H-23),5.38(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.00(C-4),101.90(C-12),87.81(C-5),81.04(C-6),66.43(C-16),59.31(C-22),57.68(C-20),55.42(C-17),53.06(C-19),52.76(C-18),52.49(C-1),44.35(C-7),37.42(C-11),36.35(C-10),34.56(C-3),30.84(C-9),26.97(C-17),26.12(C-8),24.61(C-15),24.40(C-2),20.30(C-14),12.97(C-13).HR MS:C24H42N2O6[M+H]+计算值455.3116,测定值455.3115.
2b-4:黄色油状物；(c 1.5mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.5Hz,H-13),0.96(3H,d,J＝6.0Hz,H-14),1.43(3H,s,H-15),1.47(9H,s,H-23),1.26-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.32-2.43(1H,m,H-1),2.61-2.64(1H,m,H-11),3.40-3.46(11H,m,H-16,H-18～H-20),3.92-4.00(1H,m,H-16),4.19(2H,t,J＝6.3Hz,H-14),4.76(1H,s,H-12),5.37(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.6(C-21),104.0(C-4),101.9(C-12),87.8(C-5),81.0(C-6),79.7(C-22),66.5(C-16),55.3(C-18),52.6(C-20),52.5(C-19),52.0(C-1),44.4(C-7),37.4(C-11),36.4(C-10),34.6(C-3),30.8(C-9),28.4(C-23),26.4(C-17),26.1(C-8),24.6(C-15),24.4(C-2),20.4(C-14),13.0(C-13).HR MS:C27H46N2O7[M+H]+计算值511.3378,测定值511.3370.
2b-5:1H NMR(300MHz,CDCl3)δ:0.92(3H,d,J＝7.5Hz,H-13),0.96(3H,d,J＝5.7Hz,H-14),1.44(3H,s,H-15),1.23-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.32-2.42(1H,m,H-1),2.49-2.65(7H,m,H-11,H-18 and H-19),3.22-3.25(4H,m,H-20),3.40-3.48(1H,m,H-16),3.88-3.96(1H,m,H-16),4.80(1H,d,J＝2.4Hz,H-12),5.41(1H,s,H-5),6.87(1H,t,J＝7.2Hz,H-23),6.94(2H,d,J＝7.8Hz,H-21),7.25-7.30(2H,m,H-22)；13C NMR(75MHz,CDCl3)δ:151.2(C-21),129.1(C-23),119.7(C-24),116.0(C-22),104.0(C-4),102.0(C-12),87.9(C-5),81.1(C-6),66.5(C-16),55.6(C-18),53.2(C-20),52.6(C-1),49.1(C-19),44.4(C-7),37.5(C-11),36.4(C-10),34.6(C-3),30.9(C-9),28.4(C-17),26.2(C-8),24.7(C-15),24.5(C-2),20.4(C-14),13.0(C-13).HR MS:C28H42N2O5[M+H]+计算值487.3167,测定值487.3162.
实施例2、DHA唑类衍生物的合成
在100mL圆底烧瓶中依次加入唑类化合物YH、N,N-二甲基甲酰胺(DMF)和碱(NaH或K2CO3),搅拌15min后,加入M1,控温搅拌反应,TLC监测反应进程。反应完成后,加入乙酸乙酯(EtOAc)15mL和饱和NaCl水溶液20mL,静置分层,水层用EtOAc(10mL×2)萃取,合并有机相,饱和食盐水20mL洗涤,无水Na2SO4干燥,减压旋蒸除去EtOAc得粗品或纯品,必要时柱层析,干燥,即得目标化合物3,4,5。具体合成条件及结果见表2,3,4。
表2目标化合物3的合成条件及结果
表3目标化合物4的合成条件及结果
表4目标化合物5的合成条件及结果
目标化合物3-5的表征数据如下：
3a-1:m.p.:93.7-95.1℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.80(3H,d,J＝7.4Hz,H-14),0.93(3H,d,J＝5.5Hz,H-13),1.42(3H,s,H-15),1.17-2.08(10H,m,H-2,H-3,H-7～H-10),2.34(1H,td,J＝14.0,3.9Hz,H-1),2.51-2.65(1H,m,H-11),3.68-3.81(1H,m,H-16),4.19-4.41(3H,m,H-16 and H-17),4.75(1H,d,J＝3.4Hz,H-12),5.13(1H,s,H-5),6.23(s,1H,H-19),7.42(1H,s,H-20),7.51(1H,s,H-20)；13CNMR(75MHz,CDCl3)δ:139.29(C-20),129.67(C-19),105.16(C-18),103.98(C-4),101.87(C-12),87.70(C-5),80.89(C-6),66.66(C-16),52.37(C-1),51.99(C-17),44.10(C-7),37.11(C-11),36.29(C-10),34.46(C-3),30.62(C-9),26.08(C-8),24.57(C-15),24.14(C-2),20.29(C-14),12.81(C-13).HR MS:C20H30N2O5(M+Na)+计算值401.2047,测定值401.2050.
3a-2:黄色油状物；(c 1.1mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.85(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝6.1Hz,H-13),1.44(3H,s,H-15),1.22-2.07(10H,m,H-2,H-3,H-7～H-10),2.32-2.38(1H,m,H-1),2.61-2.63(1H,m,H-11),3.62-3.68(1H,m,H-16),4.15-4.21(3H,m,H-16 and H-17),4.76(1H,s,H-12),5.11(1H,s,H-5),7.00(1H,s,H-19),7.09(1H,s,H-18),7.62(1H,s,H-20)；13C NMR(75MHz,CDCl3)δ:128.7(C-20),123.1(C-19),118.9(C-18),104.1(C-4),102.0(C-12),87.8(C-5),80.8(C-6),67.0(C-16),52.3(C-1),47.2(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.3(C-2),20.3(C-14),13.0(C-13).HR MS:C20H30N2O5(M+H)+计算值379.2228,测定值379.2221.
3a-3:黄色油状物；(c 1.1mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝6.9Hz,H-14),0.95(3H,d,J＝6.3Hz,H-13),1.45(3H,s,H-15),1.19-2.06(10H,m,H-2,H-3,H-7～H-10),2.12(3H,s,H-21),2.32-2.43(1H,m,H-1),2.59-2.66(1H,m,H-11),3.40-3.52(4H,m,H-16 and H-17),4.69(1H,d,J＝2.7Hz,H-12),5.39(1H,s,H-5)；13CNMR(75MHz,CDCl3)δ:127.8(C-18),127.2(C-20),118.8(C-19),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.9(C-16),52.4(C-1),47.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.7(C-21).HR MS:C21H32N2O5(M+H)+计算值393.2384,测定值393.2382.
3a-4:黄色油状物；(c 1.1mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.85(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝4.8Hz,H-13),1.43(3H,s,H-15),1.22-2.07(10H,m,H-2,H-3,H-7～H-10),2.29-2.34(1H,m,H-1),2.41(3H,s,H-21),2.61-2.63(1H,m,H-11),3.58-3.63(1H,m,H-16),3.99-4.16(3H,m,H-16 and H-17),4.76(1H,d,J＝3.3Hz,H-12),5.08(1H,s,H-5).6.88(1H,s,H-19),6.92(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:126.7(C-20 and C-19),118.9(C-18),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.8(C-16),52.4(C-1),45.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.9(C-21).HR MS:C21H32N2O5(M+H)+计算值393.2384,测定值393.2386.
3a-5:黄色油状物；(c 1.0mg/mL,CH2Cl2).1H NMR(300MHz,CDCl3)δ:0.81(3H,d,J＝7.2Hz,H-14),0.87(3H,d,J＝6.3Hz,H-13),1.42(3H,s,H-15),1.26-2.08(10H,m,H-2,H-3,H-7～H-10),2.29-2.37(1H,m,H-1),2.21(3H,s,H-21),2.28(3H,s,H-22),2.51-2.59(1H,m,H-11),3.64-3.69(1H,m,H-16),4.12-4.28(3H,m,H-16 and H-17),4.75(1H,d,J＝2.7Hz,H-12),5.07(1H,s,H-5).5.86(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:147.4(C-20),139.4(C-19),104.6(C-4),103.9(C-19),101.7(C-12),87.6(C-5),80.9(C-6),66.4(C-16),52.3(C-1),47.9(C-17),44.2(C-7),37.0(C-11),36.3(C-10),34.6(C-3),30.7(C-9),26.1(C-8),24.5(C-15),24.0(C-2),20.2(C-14),13.0(C-13),12.8(C-21),11.1(C-22)；HR MS:C22H34N2O5(M+Na)+计算值429.2360,测定值429.2356.
3a-6:黄色油状物；(c 1.0mg/mL,CH2Cl2).1H NMR(300MHz,CDCl3)δ:0.76(3H,d,J＝7.5Hz,H-14),0.83(3H,d,J＝6.0Hz,H-13),1.39(3H,s,H-15),1.15-1.99(10H,m,H-2,H-3,H-7～H-10),2.24-2.35(H,m,H-1),2.52-2.59(H,m,H-11),3.70-3.76(1H,m,H-16),4.28-4.43(3H,m,H-16 and H-17),4.73(1H,d,J＝2.7Hz,H-12),4.91(1H,s,H-5),7.30(2H,t,J＝2.4Hz,H-21 and H-22),7.42(1H,d,J＝7.5Hz,H-23),7.80(1H,d,J＝7.5Hz,H-20),7.95(1H,s,H-18).
3b-1:m.p.:109.3-110.2℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝6.9Hz,H-14),0.96(3H,d,J＝5.6Hz,H-13),1.44(3H,s,H-15),1.17-2.22(12H,m,H-2,H-3,H-7～H-10 and H-17),2.37(1H,m,H-1),2.59-2.72(1H,m,H-11),3.28-3.36(1H,m,H-16),3.82-3.89(1H,m,H-16),4.23(2H,t,J＝7.0Hz,H-18),4.78(1H,d,J＝3.3Hz,H-12),5.40(1H,s,H-5),6.25(1H,s,H-20),7.37(1H,s,H-19),7.52(1H,s,H-21)；13C NMR(75MHz,CDCl3)δ:139.31(C-21),129.09(C-20),105.25(C-19),104.06(C-4),102.01(C-12),87.84(C-5),81.00(C-6),64.96(C-16),52.47(C-1),49.00,44.29(C-7),37.38(C-11),36.33(C-10),34.54(C-3),30.82(C-17),30.49(C-9),26.13(C-8),24.62(C-15),24.46(C-2),20.33(C-14),13.09(C-13).HR MS:C21H32N2O5(M+Na)+计算值415.2203,测定值415.2202.
3b-2:黄色浆状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.94-0.98(6H,m,H-13 and H-14),1.43(3H,s,H-15),1.25-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.33-2.42(1H,m,H-1),2.60-2.71(1H,m,H-11),3.33-3.40(1H,m,H-16),3.83-3.90(1H,m,H-16),4.04(2H,t,J＝7.2Hz,H-18),4.78(1H,s,H-12),5.37(1H,s,H-5),6.91(1H,s,H-20),7.07(1H,s,H-19),7.47(1H,s,H-21)；13C NMR(75MHz,CDCl3)δ:137.1(21),129.5(C-20),118.8(C-19),104.1(C-4),102.0(C-12),87.9(C-5),80.9(C-6),64.4(C-16),52.5(C-1),44.2(C-7),43.8(C-18),37.5(C-11),36.3(C-10),34.5(C-3),31.2(C-17),30.8(C-9),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.1(C-13).HR MS:C21H32N2O5[M+H]+计算值393.2384,测定值393.2386.
3b-3:黄色油状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝6.9Hz,H-14),0.95(3H,d,J＝6.3Hz,H-13),1.45(3H,s,H-15),1.19-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.13(3H,s,H-22),2.32-2.43(1H,m,H-1),2.59-2.66(1H,m,H-11),3.40-3.52(4H,m,H-16 and H-18),4.69(1H,d,J＝2.7Hz,H-12),5.39(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:127.9(C-19),127.2(C-21),118.9(C-20),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.9(C-16),52.4(C-1),47.8(C-18),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),29.7(C-17),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.7(C-21).HRMS:C22H34N2O5[M+H]+计算值407.2540,测定值407.2542.
3b-4:黄色油状物；(c 1.7mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.85(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝4.8Hz,H-13),1.43(3H,s,H-15),1.22-2.07(12H,m,H-2,H-3,H-7～H-10 and H-17),2.29-2.34(1H,m,H-1),2.41(3H,s,H-21),2.61-2.63(1H,m,H-11),3.58-3.63(1H,m,H-16),3.99-4.16(3H,m,H-16 and H-17),4.76(1H,d,J＝3.3Hz,H-12),5.08(1H,s,H-5).6.88(1H,s,H-20),6.92(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:126.7(C-20 and C-19),118.9(C-18),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),66.8(C-16),52.4(C-1),45.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),29.6(C-17),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.9(C-21).HR MS:C22H34N2O5[M+H]+计算值407.2540,测定值407.2537.
3b-5:黄色油状物；(c 2.5mg/mL,CHCl3).1H NMR(400MHz,CDCl3)δ:0.93(3H,d,J＝7.4Hz,H-13),0.96(3H,d,J＝7.4Hz,H-14),1.44(3H,s,H-15),1.37-2.12(12H,m,H-2,H-3,H-7～H-10 and H-17),2.21(3H,s,H-21),2.29(3H,s,H-22),2.39(1H,m,H-1),2.61-2.68(1H,m,H-11),3.36-3.41(1H,m,H-16),3.85-3.90(1H,m,H-16),4.03(2H,t,J＝7.1Hz,H-18),4.80(1H,d,J＝2.4Hz,H-12),5.45(1H,s,H-5),5.77(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:147.18(C-21 and C-23),138.39(C-20),104.77(C-4),103.98(C-20),101.79(C-12),87.81(C-5),80.97(C-6),65.07(C-16),52.44(C-1),45.56(C-17),44.30(C-7),37.30(C-11),36.31(C-10),34.54(C-3),30.79(C-9),30.53(C-18),26.07(C-8),24.59(C-15),24.43(C-2),20.27(C-14),13.39(C-13),13.02(C-13),10.85(C-22 and C-23).HR MS:C23H36N2O5[M+Na]+计算值443.2516,测定值443.2518.
3b-6:黄色浆状物；(c 1.5mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.87(3H,d,J＝6.9Hz,H-13),0.98(3H,d,J＝7.5Hz,H-14),1.44(3H,s,H-15),1.26-2.16(12H,m,H-2,H-3,H-7～H-10 and H-17),2.33-2.43(1H,m,H-1),2.68-2.71(1H,m,H-11),3.39-3.47(1H,m,H-16),3.88-3.95(1H,m,H-16),4.30(2H,t,J＝7.2Hz,H-18),4.82(1H,d,J＝2.4Hz,H-12),5.40(1H,s,H-5),7.30-7.33(2H,m,H-22 and H-23),7.41(1H,d,J＝4.8Hz,H-21),7.82-7.85(1H,m,H-24),7.98(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:129.1(C-21 and C-24),116.1(C-22 and C-23),104.0(C-4),102.0(C-12),87.8(C-5),81.0(C-6),66.4(C-16),52.5(C-1),49.0(C-18),44.0(C-7),37.5(C-11),36.4(C-10),34.6(C-3),30.7(C-9),29.7(C-17),26.2(C-8),24.7(C-15),24.5(C-2),20.4(C-14),13.0(C-13).HRMS:C25H34N2O5[M+H]+计算值443.2541,测定值443.2538.
4a-1:m.p.:100.8-102.4℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.74(3H,d,J＝7.2Hz,H-14),0.93(3H,d,J＝5.4Hz,H-13),1.42(3H,s,H-15),1.12-2.11(10H,m,H-2,H-3,H-7～H-10),2.34(1H,m,H-1),2.47-2.63(1H,m,H-11),3.89-3.96(1H,m,H-16),4.33-4.40(1H,m,H-16),4.64(2H,m,H-17),4.77(1H,s,H-12),5.21(1H,s,H-5),7.60(2H,s,H-18)；13C NMR(75MHz,CDCl3)δ:133.96(C-18),103.97(C-4),102.10(C-12),87.79(C-5),80.92(C-6),66.12(C-16),54.73(C-17),52.37(C-1),44.12(C-7),37.13(C-11),36.29(C-10),34.47(C-3),30.58(C-9),26.08(C-8),24.58(C-15),23.93(C-2),20.31(C-14),12.67(C-13).HR MS:C19H29N3O5[M+Na]+计算值402.1999,测定值402.1997.
4a-2:m.p.:128.4-129.7℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.81(3H,d,J＝7.2Hz,H-14),0.95(3H,d,J＝5.4Hz,H-13),1.42(3H,s,H-15),1.16-2.08(10H,m,H-2,H-3,H-7～H-10),2.35(1H,m,H-1),2.56-2.65(1H,m,H-11),3.77-3.84(1H,m,H-16),4.26-4.33(1H,m,H-16),4.52-4.60(1H,m,H-17),4.63-4.72(1H,m,H-17),4.78(1H,d,J＝3.2Hz,H-12),5.16(1H,s,H-5),7.62(1H,s,H-18),7.72(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:133.62(C-19),123.94(C-18),104.11(C-4),102.06(C-12),87.77(C-5),80.78(C-6),66.46(C-16),52.33(C-1),50.12(C-17),43.97(C-7),37.18(C-11),36.23(C-10),34.35(C-3),30.54(C-9),26.04(C-8),24.51(C-15),24.19(C-2),20.30(C-14),12.80(C-13).HR MS:C19H29N3O5[M+Na]+计算值402.1999,测定值402.1993.
4a-3:m.p.:93.5-95.2℃；(c 1.1mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.78(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝4.5Hz,H-13),1.42(3H,s,H-15),1.19-2.08(10H,m,H-2,H-3,H-7～H-10),2.31-2.39(1H,m,H-1),2.58-2.62(1H,m,H-11),3.74-3.81(1H,m,H-16),4.09-4.17(1H,m,H-16),4.36-4.38(2H,m,H-17),4.78(1H,s,H-12),5.17(1H,s,H-5),7.96(1H,s,H-19),8.12(1H,s,H-18).
4a-4:m.p.:100.5～104.3℃；(c 3.0mg/mL,CH2Cl2).1H NMR(300MHz,CDCl3)δ:0.89(3H,d,J＝7.4Hz,H-14),0.96(3H,d,J＝5.6Hz,H-13),1.44(3H,s,H-15),1.27-2.10(10H,m,H-2,H-3,H-7～H-10),2.37(1H,td,J＝14.2,3.7Hz,H-1),2.63-2.74(1H,m,H-11),3.61-3.70(1H,m,H-16),4.08-4.23(3H,m,H-16 and H-17),4.81(1H,d,J＝3.5Hz,H-12),5.27(1H,s,H-5),7.80(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:154.04,140.14,104.17,102.24,87.74,80.72,66.47,52.25,43.91,43.51,37.23,36.18,34.25,30.49,25.95,24.47,24.40,20.21,12.83.HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2105.
4a-5:m.p.:97.3-98.5℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝7.4Hz,H-14),0.94(3H,d,J＝6.3Hz,H-13),1.41(3H,s,H-15),1.21-2.09(10H,m,H-2,H-3,H-7～H-10),2.37(1H,td,J＝14.1,3.6Hz,H-1),2.54-2.69(1H,m,H-11),3.23(2H,t,J＝5.8Hz,H-17),3.82-3.66(1H,m,H-16),3.98-4.06(1H,m,H-16),4.83(1H,d,J＝3.2Hz,H-12),5.06(2H,s,H-20),5.57(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:163.32,148.19,104.35,101.96,88.16,81.26,67.28,52.40,44.26,37.28,36.30,34.52,32.05,30.87,25.94,24.52,24.33,20.33,12.93.HR MS:C19H30N4O5S[M-H]-计算值425.1864,测定值425.1866.
4a-6:m.p.:139.3-140.5℃；(c 0.8mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.63(3H,d,J＝7.5Hz,H-13),0.85(3H,d,J＝6.0Hz,H-14),1.39(3H,s,H-15),0.97-1.99(10H,m,H-2,H-3,H-7～H-10),2.23-2.34(1H,m,H-1),2.47-2.50(1H,m,H-11),3.88-3.93(1H,m,H-16),4.45-4.52(1H,m,H-16),4.73(1H,d,J＝3.0Hz,H-12),4.80-4.93(3H,m,H-5 and H-17),7.37(1H,t,J＝7.5Hz,H-21),7.49(1H,t,J＝7.2Hz,H-20),7.57(1H,d,J＝8.1Hz,H-19),7.86(2H,d,J＝8.4Hz,H-22)；13C NMR(75MHz,CDCl3)δ:145.8(C-23),133.5(C-18),127.1(C-21),123.8(C-20),119.8(C-22),109.6(C-19),104.0(C-4),102.0(C-12),87.6(C-5),80.7(C-6),66.1(C-16),52.2(C-1),48.0(C-17),43.9(C-7),36.9(C-11),36.2(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.4(C-15),24.0(C-2),20.2(C-14),12.6(C-13).HR MS:C23H31N3O5[M+Na]+计算值452.2156,测定值452.2151.
4a-7:m.p.:65.6-67.3℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.73(3H,d,J＝6.9Hz,H-13),0.87(3H,d,J＝7.5Hz,H-14),1.42(3H,s,H-15),1.01-1.99(10H,m,H-2,H-3,H-7～H-10),2.25-2.33(1H,m,H-1),2.49-2.55(1H,m,H-11),4.00-4.04(1H,m,H-16),4.62-4.68(1H,m,H-16),4.81(1H,s,H-12),4.89-5.03(3H,m,H-5and H-17),7.38(1H,d,J＝9.0Hz,H-20),7.86(2H,d,J＝9.3Hz,H-19)；13C NMR(75MHz,CDCl3)δ:143.5(C-18),126.2(C-20),117.9(C-19),103.9(C-4),101.7(C-12),87.7(C-5),80.8(C-6),65.5(C-16),56.5(C-17),52.2(C-1),44.0(C-7),36.7(C-11),36.3(C-10),34.3(C-3),30.6(C-9),26.1(C-8),24.5(C-15),23.9(C-2),20.1(C-14),12.7(C-13).HRMS:C23H31N3O5[M+Na]+计算值452.2156,测定值452.2159.
4a-8:m.p.:131.2-132.7℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝7.2Hz,H-14),0.95(3H,d,J＝6.0Hz,H-13),1.44(3H,s,H-15),1.26-2.06(10H,m,H-2,H-3,H-7～H-10),2.32-2.43(H,m,H-1),2.65-2.72(H,m,H-11),3.83～3.90(1H,m,H-16),4.22-4.29(1H,m,H-16),4.75(2H,t,J＝3.6Hz,H-17),4.87(1H,s,H-12),5.45(1H,s,H-5),7.40(1H,t,J＝7.5Hz,H-21),7.52(1H,t,J＝7.5Hz,H-20),7.62(1H,d,J＝8.4Hz,H-22),8.03(1H,d,J＝8.4Hz,H-19)；13C NMR(75MHz,CDCl3)δ:143.5(C-23),127.9(C-18),127.4(C-19),124.6(C-21),120.3(C-20),108.6(C-22),104.1(C-4),102.3(C-12),88.0(C-5),81.0(C-6),79.7(C-17),65.5(C-16),52.5(C-1),44.3(C-7),37.3(C-11),36.3(C-10),34.5(C-3),30.7(C-9),26.1(C-8),24.6(C-15),24.3(C-2),20.3(C-14),12.9(C-13).HR MS:C23H31N3O6[M+Na]+计算值468.2105,测定值468.2098.
4b-1:m.p.:100.8-102.4℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝7.2Hz,H-14).,0.96(3H,d,J＝6.2Hz,H-13),1.43(3H,s,H-15),1.17-2.10(10H,m,H-2,H-3,H-7～H-10),2.16-2.28(2H,m,H-17),2.37(1H,m,H-1),2.56-2.72(1H,m,H-11),3.26-3.43(1H,m,H-16),3.81-3.88(1H,m,H-16),4.54(2H,m,H-18),4.79(1H,d,J＝3.2Hz,H-12),5.44(1H,s,H-5),7.59(2H,s,H-18)；13C NMR(75MHz,CDCl3)δ:133.98(C-19),104.00(C-4),102.09(C-12),87.85(C-5),81.05(C-6),64.78(C-16),52.51(C-17),51.86(C-1),44.34(C-7),37.29(C-11),36.36(C-10),34.59(C-3),30.84(C-9),29.88(C-18),26.15(C-8),24.64(C-15),24.43(C-2),20.35(C-14),13.01(C-13).HR MS:C20H31N3O5[M+Na]+计算值416.2156,测定值416.2155.
4b-2:m.p.:100.8-102.4℃；(c 3.5mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝7.2Hz,H-14),0.96(3H,d,J＝6.1Hz,H-13),1.43(3H,s,H-15),1.21-2.25(12H,m,H-2,H-3,H-7～H-10 and H-17),2.28-2.43(1H,m,H-1),2.65(1H,m,H-11),3.31-3.43(1H,m,H-16),3.83-3.94(1H,m,H-16),4.46-4.52(2H,m,H-17),4.78(1H,d,J＝3.2Hz,H-12),5.40(1H,s,H-5),7.56(1H,s,H-18),7.72(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:133.77(C-20),123.48(C-19),104.10(C-4),102.04(C-12),87.84(C-5),80.94(C-6),64.52(C-16),52.41(C-1),47.19(C-17),44.18(C-7),37.34(C-11),36.27(C-10),34.46(C-3),30.75(C-9),30.41(C-18),26.08(C-8),24.56(C-15),24.45(C-2),20.31(C-14),13.04(C-13).HR MS:C20H31N3O5[M+Na]+计算值416.2156,测定值416.2157.
4b-3:黄色油状物；(c 1.7mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.92-0.97(6H,m,H-14 and H-13),1.43(3H,s,H-15),1.19-2.08(10H,m,H-2,H-3,H-7～H-10),2.16-2.19(2H,m,H-17),2.32-2.36(1H,m,H-1),2.64-2.67(1H,m,H-11),3.32-3.40(1H,m,H-16),3.84-3.91(1H,m,H-16),4.28(2H,t,J＝6.9Hz,H-18),4.77(1H,s,H-12),5.39(1H,s,H-5),7.96(1H,s,H-20),8.09(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:151.9(C-20),143.0(19),104.1(C-4),102.0(C-12),87.8(C-5),80.9(C-6),64.5(C-16),52.4(C-1),46.7(C-18),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),30.7(C-9),29.9(C-18),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C20H31N3O5[M+Na]+计算值416.2156,测定值416.2155.
4b-4:黄色浆状物；(c 1.5mg/mL,CH2Cl2).1H NMR(300MHz,CDCl3)δ:0.93(3H,d,J＝7.4Hz,H-14),0.96(3H,d,J＝5.1Hz,H-13),1.43(3H,s,H-15),1.25-2.15(12H,m,H-2,H-3,H-7～H-10 and H-17),2.37(1H,td,J＝14.0,3.8Hz,H-1),2.62-2.71(1H,m,H-11),3.55-3.62(1H,m,H-16),3.84-3.92(1H,m,H-16),3.97-4.08(2H,m,H-18),4.81(1H,d,J＝3.3Hz,H-12),5.44(1H,s,H-5),7.65(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:153.99,142.09,104.21,101.97,87.84,80.88,64.67,52.43,46.28,44.22,37.41,36.26,34.45,30.77,29.32,26.04,24.59,24.46,20.28,13.06.HR MS:C20H32N4O5[M+Na]+计算值431.2265,测定值431.2266.
4b-5:黄色浆状物；(c 2.9mg/mL,CH2Cl2).1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝7.4Hz,H-14),0.94(3H,d,J＝6.3Hz,H-13),1.41(3H,s,H-15),1.21-2.09(12H,m,H-2,H-3,H-7～H-10 and H-17),2.37(1H,td,J＝14.1,3.6Hz,H-1),2.54-2.69(1H,m,H-11),3.23(2H,t,J＝5.8Hz,H-18),3.66-3.82(1H,m,H-16),3.98-4.06(1H,m,H-16),4.80(1H,d,J＝3.2Hz,H-12),5.44(2H,s,H-21),5.57(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:163.55,148.20,104.21,101.97,87.93,80.93,64.67,52.43,44.22,37.40,36.31,34.50,30.87,29.65,26.11,24.59,24.46,20.31,13.06.HR MS:C20H32N4O5S[M+Na]+计算值463.1986,测定值463.1986.
4b-6:黄色浆状物；(c 1.3mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝7.5Hz,H-13),0.97(3H,d,J＝6.9Hz,H-14),1.42(3H,s,H-15),1.21-2.06(10H,m,H-2,H-3,H-7～H-10),2.31-2.44(3H,m,H-1 and H-17),2.60-2.70(1H,m,H-11),3.37-3.45(1H,m,H-16),3.86-3.93(1H,m,H-16),4.79-4.87(3H,m,H-12 and H-18),5.50(1H,s,H-5),7.37-7.41(2H,m,H-21),7.84-7.88(2H,m,H-20)；13C NMR(75MHz,CDCl3)δ:144.3(C-19),126.3(C-21),117.9(C-20),104.0(C-4),102.1(C-12),87.9(C-5),81.1(C-6),64.8(C-16),53.7(C-18),52.6(C-1),44.4(C-7),37.3(C-11),36.4(C-10),34.6(C-3),30.7(C-9),26.2(C-8),24.7(C-15),24.5(C-2),22.7(C-17),20.4(C-14),13.0(C-13).HRMS:C24H33N3O5[M+Na]+计算值466.2312,测定值466.2309.
4b-7:黄色浆状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.95-0.98(6H,m,H-13 and H-14),1.43(3H,s,H-15),1.26-2.09(10H,m,H-2,H-3,H-7～H-10),2.28-2.42(3H,m,H-1 and H-17),2.65-2.70(1H,m,H-11),3.41-3.48(1H,m,H-16),3.88-3.95(1H,m,H-16),4.72-4.78(2H,m,H-18),4.81(1H,d,J＝3.3Hz,H-12),5.44(3H,s,H-5),7.38(1H,t,J＝7.5Hz,H-21),7.46-7.55(2H,m,H-22 and H-23),8.08(1H,d,J＝7.8Hz,H-20)；13C NMR(75MHz,CDCl3)δ:145.9(C-19),133.0(C-24),127.3(C-21),123.9(C-22),120.0(C-20),109.2(C-23),104.2(C-4),102.1(C-12),87.9(C-5),81.0(C-6),64.8(C-16),52.5(C-1),45.3(C-18),44.3(C-7),37.4(C-11),36.3(C-10),34.6(C-3),30.6(C-9),29.9(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.1(C-13).HR MS:C24H33N3O5[M+Na]+计算值466.2312,测定值466.2310.
4b-8:m.p.:106.3-108.1℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.88(3H,d,J＝9.3Hz,H-14),0.93(3H,d,J＝7.2Hz,H-13),1.45(3H,s,H-15),1.22-2.03(10H,m,H-2,H-3,H-7～H-10),2.13-2.17(2H,m,H-17),2.32-2.42(H,m,H-1),2.64-2.71(H,m,H-11),3.62-3.67(1H,m,H-16),4.10～4.18(1H,m,H-16),4.66(2H,t,J＝6.0Hz,H-18),4.85(1H,s,H-12),5.43(1H,s,H-5),7.40(1H,t,J＝7.2Hz,H-21),7.52(1H,t,J＝7.2Hz,H-22),7.59(1H,d,J＝7.8Hz,H-23),8.02(1H,d,J＝8.7Hz,H-20)；13C NMR(75MHz,CDCl3)δ:143.5(C-24),127.9(C-19),127.3(C-20),124.5(C-22),120.3(C-21),108.5(C-23),104.1(C-4),102.1(C-12),87.9(C-5),81.0(C-6),77.4(C-18),64.1(C-16),52.5(C-1),44.3(C-7),37.3(C-11),36.4(C-10),34.5(C-3),30.8(C-9),28.6(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C24H33N3O6[M+Na]+计算值482.2262,测定值482.2260.
5a-1:m.p.:135.2-136.5℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.72(3H,d,J＝7.8Hz,H-13),0.95(3H,d,J＝5.1Hz,H-14),1.43(3H,s,H-15),1.25-2.06(10H,m,H-2,H-3,H-7～H-10),2.31-2.40(1H,m,H-1),2.63-2.65(1H,m,H-11),3.80-3.86(1H,m,H-16),4.28-4.35(1H,m,H-16),4.63(2H,t,J＝4.8Hz,H-18),4.79(1H,s,H-12),5.19(1H,s,H-5),8.64(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:143.0(C-18),104.2(C-4),102.3(C-12),87.9(C-5),80.7(C-6),65.7(C-16),52.3(C-1),48.4(C-17),43.9(C-7),37.3(C-11),36.3(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.5(C-15),24.3(C-2),20.3(C-14),12.8(C-13).HR MS:C18H28N4O5[M+Na]+计算值403.1952,测定值403.1951.
5a-2:m.p.:123.2-124.6℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.72(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝4.8Hz,H-14),1.43(3H,s,H-15),1.24-2.05(10H,m,H-2,H-3,H-7～H-10),2.31-2.39(1H,m,H-1),2.54-2.61(1H,m,H-11),3.96-4.03(1H,m,H-16),4.38-4.45(1H,m,H-16),4.78(1H,s,H-12),4.87(2H,t,J＝4.8Hz,H-17),5.22(1H,s,H-5),8.52(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:152.8(C-18),104.1(C-4),102.2(C-12),87.9(C-5),80.9(C-6),65.5(C-16),53.1(C-17),52.4(C-1),44.1(C-7),37.3(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.0(C-2),20.3(C-14),12.6(C-13).HR MS:C18H28N4O5[M+Na]+计算值403.1952,测定值403.1949.
5a-3:m.p.:117.4-119.1℃；(c 1.1mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.93(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝5.7Hz,H-13),1.43(3H,s,H-15),1.26-2.07(10H,m,H-2,H-3,H-7～H-10),2.32-2.42(1H,m,H-1),2.56(1H,s,H-20),2.62-2.73(1H,m,H-11),3.41-3.49(1H,m,H-16),3.87-3.94(1H,m,H-16),4.33-4.38(2H,m,H-18),4.80(1H,s,H-12),5.40(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:162.75,103.96,102.03,87.79,80.89,64.22,52.46,49.83,44.24,37.22,36.29,34.53,30.73,26.03,24.58,24.39,20.27,12.90,10.76.HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2106.
5a-4:m.p.:114.2-115.7℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.75(3H,d,J＝7.2Hz,H-14),0.94(3H,d,J＝4.5Hz,H-13),1.42(3H,s,H-15),1.21-2.04(10H,m,H-2,H-3,H-7～H-10),2.29-2.38(1H,m,H-1),2.57(3H,s,H-19),2.58-2.61(1H,m,H-11),3.80-3.87(1H,m,H-16),4.34-4.37(1H,m,H-16),4.46-4.48(2H,m,H-17),4.76(1H,s,H-12),5.11(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:152.1(C-18),104.2(C-4),102.3(C-12),87.7(C-5),80.7(C-6),65.8(C-16),52.3(C-1),47.0(C-17),43.9(C-7),37.2(C-11),36.2(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.5(C-15),24.2(C-2),20.3(C-14),13.0(C-13),8.9(C-19).HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2106.
5a-5:m.p.:121.7-123.3℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.90(3H,d,J＝7.5Hz,H-14),0.96(3H,d,J＝6.3Hz,H-13),1.43(3H,s,H-15),1.21-2.04(10H,m,H-2,H-3,H-7～H-10),2.32-2.43(H,m,H-1),2.61-2.66(H,m,H-11),3.63(2H,t,J＝5.7Hz,H-17),3.75-3.83(1H,m,H-16),3.93(3H,s,H-19),4.12-4.19(H,m,H-16),4.83(1H,d,J＝2.7Hz,H-12),5.43(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.0(C-18),104.1(C-4),102.2(C-12),87.9(C-5),80.9(C-6),66.5(C-16),52.4(C-1),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),33.6(C-17),33.4(C-19),30.7(C-9),26.1(C-8),24.6(C-15),24.3(C-2),20.3(C-14),12.9(C-13).HR MS:C19H30N4O5S[M+Na]+计算值449.1829,测定值449.1821.
5a-6:m.p.:129.8-130.8℃；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.87(3H,d,J＝6.9Hz,H-13),0.98(3H,d,J＝7.5Hz,H-14),1.44(3H,s,H-15),1.26-2.12(10H,m,H-2,H-3,H-7～H-10),2.33-2.43(1H,m,H-1),2.68-2.71(1H,m,H-11),3.94-4.00(1H,m,H-16),4.52-4.59(1H,m,H-16),4.78-4.82(1H,m,H-17),4.83(1H,d,J＝2.7Hz,H-12),4.91-4.99(1H,m,H-17),5.15(1H,s,H-5),7.47-7.50(3H,m,H-21 and H-22),8.17(1H,d,J＝5.4Hz,H-20)；13C NMR(75MHz,CDCl3)δ:165.1(C-18),130.3(C-22),128.8(C-21),127.3(C-19),126.7(C-20),104.0(C-4),102.0(C-12),87.8(C-5),80.8(C-6),64.9(C-16),52.1(C-1),52.3(C-17),44.0(C-7),37.1(C-11),36.3(C-10),34.2(C-3),30.6(C-9),26.1(C-8),24.4(C-15),24.0(C-2),20.0(C-14),12.87(C-13).HR MS:C24H32N4O5[M+Na]+计算值479.2265,测定值479.2268.
5b-1:黄色油状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.94(3H,d,J＝7.8Hz,H-13),0.97(3H,d,J＝6.6Hz,H-14),1.44(3H,s,H-15),1.26-2.06(10H,m,H-2,H-3,H-7～H-10),2.22-2.28(2H,m,H-17),2.33-2.42(1H,m,H-1),2.63-2.70(1H,m,H-11),3.39-3.46(1H,m,H-16),3.87-3.94(1H,m,H-16),4.54(2H,t,J＝6.9Hz,H-18),4.79(H,s,H-12),5.39(1H,s,H-5),8.62(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:142.6(C-19),104.2(C-4),102.2(C-12),87.9(C-5),80.9(C-6),64.3(C-16),52.4(C-1),45.5(C-18),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),30.7(C-9),30.0(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2111.
5b-2:黄色油状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.93-0.98(6H,m,H-13 and H-14),1.43(3H,s,H-15),1.26-2.06(10H,m,H-2,H-3,H-7～H-10),2.28-2.32(2H,m,H-17),2.37-2.43(1H,m,H-1),2.61-2.68(1H,m,H-11),3.35-3.42(1H,m,H-16),3.86-3.92(1H,m,H-16),4.74-4.79(3H,m,H-12 and H-18),5.41(1H,s,H-5),8.51(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:152.8(C-19),104.1(C-4),102.2(C-12),87.9(C-5),81.0(C-6),64.4(C-16),52.5(C-1),50.2(C-18),44.3(C-7),37.4(C-11),36.4(C-10),34.6(C-3),30.8(C-9),29.5(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C19H30N4O5[M+Na]+计算值417.2108,测定值417.2114.
5b-3:黄色油状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.93(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝5.7Hz,H-13),1.43(3H,s,H-15),1.26-2.07(10H,m,H-2,H-3,H-7～H-10),2.16-2.22(2H,m,H-17),2.32-2.42(1H,m,H-1),2.56(1H,s,H-20),2.62-2.73(1H,m,H-11),3.41-3.49(1H,m,H-16),3.87-3.94(1H,m,H-16),4.33-4.38(2H,m,H-18),4.80(1H,s,H-12),5.40(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:162.75(C-19),103.96(C-4),102.03(C-12),87.79(C-5),80.89(C-6),64.22(C-16),52.46(C-1),49.83(C-18),44.24(C-7),37.22(C-11),36.29(C-10),34.53(C-3),30.73(C-9),29.38(C-17),26.03(C-8),24.58(C-15),24.39(C-2),20.27(C-14),12.90(C-13),10.76(C-20).HRMS:C20H32N4O5[M+Na]+计算值431.2265,测定值431.2272.
5b-4:黄色油状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.93(3H,d,J＝7.5Hz,H-13),0.97(3H,d,J＝6.1Hz,H-13),1.44(3H,s,H-15),1.19-2.10(10H,m,H-2,H-3,H-7～H-10),2.14-2.27(2H,m,H-17),2.32-2.47(1H,m,H-1),2.57(3H,s,H-20),2.64-2.73(1H,m,H-11),3.39-3.59(1H,m,H-16),3.88-3.95(1H,m,H-16),4.33-4.43(2H,m,H-18),4.81(1H,d,J＝3.3Hz,H-12),5.41(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.16(C-4),102.01(C-12),87.87(C-5),80.86(C-6),64.31(C-16),52.42(C-1),44.27(C-18),44.17(C-7),37.41(C-11),36.30(C-10),34.48(C-3),30.71(C-9),29.72(C-17),26.04(C-8),24.59(C-15),24.48(C-2),20.26(C-14),12.99(C-13),8.70(C-20).HR MS:C20H32N4O5[M+Na]+计算值431.2265,测定值431.2273.
5b-5:黄色浆状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.91(3H,d,J＝7.5Hz,H-13),0.95(3H,d,J＝6.3Hz,H-13),1.43(3H,s,H-15),1.25-2.06(12H,m,H-2,H-3,H-7～H-10 and H-17),2.32-2.41(1H,m,H-1),2.62-2.67(1H,m,H-11),3.42-3.55(3H,m,H-16 and H-18),3.92(1H,s,H-20),3.97-4.04(1H,m,H-16),4.80(1H,d,J＝3.0Hz,H-12),5.39(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.2(C-19),104.1(C-4),102.1(C-12),87.9(C-5),81.0(C-6),66.0(C-16),52.4(C-1),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),33.3(C-18),30.8(C-9),30.3(C-17),29.1(C-20),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C20H32N4O5S[M+Na]+计算值463.1986,测定值463.1985.
5b-6:白色浆状物；(c 1.0mg/mL,CHCl3).1H NMR(300MHz,CDCl3)δ:0.87(3H,d,J＝7.2Hz,H-13).0.96(3H,d,J＝6.7Hz,H-14),1.43(3H,s,H-15),1.12-2.11(10H,m,H-2,H-3,H-7～H-10),2.31-2.37(3H,m,H-1,H-17),2.62-2.72(1H,m,H-11),3.36-3.54(1H,m,H-16),3.97-4.01(1H,m,H-16),4.73-4.81(2H,m,H-18),4.82(1H,d,J＝2.7Hz,H-12),5.46(1H,s,H-5),7.42-7.58(3H,m,H-22 and H-23),8.27-8.07(2H,d,J＝5.4Hz,H-21)；13C NMR(75MHz,CDCl3)δ:165.11(C-19),130.21(C-23),128.80(C-22),127.40(C-20),126.81(C-21),104.07(C-4),102.21(C-12),87.87(C-5),80.98(C-6),64.51(C-16),52.52(C-1),50.28(C-17),44.31(C-7),37.37(C-11),36.37(C-10),34.55(C-3),30.82(C-9),29.67(C-18),26.12(C-8),24.61(C-15),24.53(C-2),20.31(C-14),12.99(C-13).HR MS:C25H34N4O5[M+Na]+计算值493.2427,测定值493.2421.
实施例3、DHA胺类衍生物和DHA唑类衍生物的K-ras/Wnt合成致死活性测试
DHA胺类衍生物和DHA唑类衍生物的K-ras/Wnt合成致死活性委托美国礼来公司Open Innovation Drug Discovery(OIDD)program进行测试，首先进行单浓度初筛(Primary SP)，然后对初步筛选出的潜力分子进行多浓度测试(Primary CRC)。结果见表5,6。
表5 K-ras/Wnt合成致死活性测试结果1
表6 K-ras/Wnt合成致死活性测试结果2
从表5和表6可以看出,本发明的DHA胺类衍生物和DHA唑类衍生物对人结直肠癌细胞(DLD-1、HCT116、SW480)具有一定的K-ras/Wnt合成致死活性；对于癌细胞DLD-1，在20μM测试浓度下，有12个化合物的K-ras/Wnt合成致死抑制活性超过50％，其中化合物2a-5、2b-5、4b-8、5b-6的抑制活性超过90％；对于癌细胞HCT116，在20μM测试浓度下的抑制活性低一些，但化合物2a-5、3b-2、5a-2的K-ras/Wnt合成致死抑制活性仍超过50％；对于癌细胞SW480，有6个化合物(2a-5、2b-5、4b-6、4b-8、5a-6、5b-6)的抑制活性超过50％，其中化合物2a-5、2b-5的K-ras/Wnt合成致死抑制活性超过80％；此外，化合物2a-5、2b-4、2b-5、4b-6、4b-8、5b-6对测试癌细胞均具有很强的K-ras/Wnt合成致死抑制活性，表现出结构优势，其中化合物4b-8具有进一步开发的潜力。本发明是首次发现DHA胺类衍生物和DHA唑类衍生物具有K-ras/Wnt合成致死抑制活性，可作为抗肿瘤药物进一步开发。
最后说明的是，以上优选实施例仅用以说明本发明的技术方案而非限制，尽管通过上述优选实施例已经对本发明进行了详细的描述，但本领域技术人员应当理解，可以在形式上和细节上对其作出各种各样的改变，而不偏离本发明权利要求书所限定的范围。
Claims (8)
1.式I所示的二氢青蒿素衍生物或其消旋体、立体异构体、互变异构体、氮氧化物、药学上可接受的盐在制备抗肿瘤药物中的应用：
式I中，n为1或2；
Y为-NR1R2、
R1和R2独立地为H、C1-C3烷基或C1-C3羟烷基；
R3为H、C1-C3烷基、C1-C3羟烷基、取代或未取代苯基、叔丁氧羰基、苄氧羰基或脂肪酰基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C3烷基；
R4和R5独立地为H或C1-C3烷基；
R6和R7独立地为H、氨基、羟基或C1-C3烷基；
R8为H、C1-C3烷基、C1-C3烷硫基、取代或未取代苯基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C3烷基。
2.如权利要求1所述的应用，其特征在于：式I中，
R1和R2独立地为H、C1-C2烷基或C1-C2羟烷基；
R3为H、C1-C2烷基、C1-C2羟烷基、取代或未取代苯基、叔丁氧羰基、苄氧羰基或烷酰基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C2烷基；
R4和R5独立地为H或C1-C2烷基；
R6和R7独立地为H、氨基、羟基或C1-C2烷基；
R8为H、C1-C2烷基、C1-C2烷硫基、取代或未取代苯基；所述苯基上的取代基为一个或多个，独立选自卤素、羟基、氨基或C1-C2烷基。
3.如权利要求2所述的应用，其特征在于：式I中，
R1和R2独立地为H、C1-C2烷基或C1-C2羟烷基；
R3为H、C1-C2烷基、C1-C2羟烷基、苯基、叔丁氧羰基、苄氧羰基或乙酰基；
R4和R5独立地为H或C1-C2烷基；
R6和R7独立地为H、氨基、羟基或C1-C2烷基；
R8为H、C1-C2烷基、C1-C2烷硫基或苯基。
4.如权利要求3所述的应用，其特征在于：式I中，
R1和R2独立地为H、甲基、乙基或羟乙基；
R3为H、甲基、羟乙基、苯基或叔丁氧羰基；
R4和R5独立地为H或甲基；
R6和R7独立地为H或氨基；
R8为H、甲基、甲硫基或苯基。
5.如权利要求4所述的应用，其特征在于：式I所示的二氢青蒿素衍生物为以下化合物中的任一种：
6.如权利要求5所述的应用，其特征在于：式I所示的二氢青蒿素衍生物为以下化合物中的任一种：2a-5,2b-4,2b-5,4b-6,4b-8,5b-6。
7.如权利要求1所述的应用，其特征在于：所述抗肿瘤药物为具有K-ras/Wnt合成致死活性的药物。
8.如权利要求1所述的应用，其特征在于：所述肿瘤为结直肠癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910786538.2A CN110403933A (zh) | 2019-08-23 | 2019-08-23 | 二氢青蒿素衍生物在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910786538.2A CN110403933A (zh) | 2019-08-23 | 2019-08-23 | 二氢青蒿素衍生物在制备抗肿瘤药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110403933A true CN110403933A (zh) | 2019-11-05 |
Family
ID=68368815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910786538.2A Pending CN110403933A (zh) | 2019-08-23 | 2019-08-23 | 二氢青蒿素衍生物在制备抗肿瘤药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110403933A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (zh) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | 青蒿琥酯衍生物及其制备方法和应用 |
| CN114933603A (zh) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | 一种青蒿素的衍生物及其制备方法与应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN167775B (zh) * | 1988-06-24 | 1990-12-22 | Hoechst India | |
| CN1038416C (zh) * | 1992-12-04 | 1998-05-20 | 中国科学院上海药物研究所 | 新型青蒿素衍生物及其制备方法 |
| CN102153564A (zh) * | 2011-01-31 | 2011-08-17 | 中国科学院上海药物研究所 | 含氮原子的青蒿素二聚体、其制备方法及用途 |
| CN103570738A (zh) * | 2012-08-07 | 2014-02-12 | 中国科学院上海生命科学研究院 | 新型青蒿素衍生物及其制法和应用 |
| CN108992414A (zh) * | 2018-06-15 | 2018-12-14 | 昆药集团股份有限公司 | 一种结直肠定位释药药物组合物及其制剂的制备方法和用途 |
-
2019
- 2019-08-23 CN CN201910786538.2A patent/CN110403933A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN167775B (zh) * | 1988-06-24 | 1990-12-22 | Hoechst India | |
| CN1038416C (zh) * | 1992-12-04 | 1998-05-20 | 中国科学院上海药物研究所 | 新型青蒿素衍生物及其制备方法 |
| CN102153564A (zh) * | 2011-01-31 | 2011-08-17 | 中国科学院上海药物研究所 | 含氮原子的青蒿素二聚体、其制备方法及用途 |
| CN103570738A (zh) * | 2012-08-07 | 2014-02-12 | 中国科学院上海生命科学研究院 | 新型青蒿素衍生物及其制法和应用 |
| CN108992414A (zh) * | 2018-06-15 | 2018-12-14 | 昆药集团股份有限公司 | 一种结直肠定位释药药物组合物及其制剂的制备方法和用途 |
Non-Patent Citations (5)
| Title |
|---|
| CHONG WU，等: "Design, Synthesis and Evaluation of the Antibacterial Enhancement Activities of Amino Dihydroartemisinin Derivatives", 《MOLECULES》 * |
| TONY FRÖHLICH，等: "ynthesis of Novel Hybrids of Thymoquinone and Artemisinin with High Activity and Selectivity Against Colon Cancer", 《CHEMMEDCHEM》 * |
| 伍治平，等: "蒿甲醚对BALB/c小鼠CT-26结直肠癌抑瘤作用", 《中国肿瘤》 * |
| 周许薇，等: "双氢青蒿素抗癌药理作用机制的研究进展", 《药学实践杂志》 * |
| 汪溪，等: "双氢青蒿素抗人结肠癌HCT116细胞作用的研究", 《实用医学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (zh) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | 青蒿琥酯衍生物及其制备方法和应用 |
| CN114933603A (zh) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | 一种青蒿素的衍生物及其制备方法与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110448552A (zh) | 二氢青蒿素衍生物在制备抗疟药物中的应用 | |
| JP7092895B2 (ja) | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の阻害剤、その医薬品及びその方法 | |
| CN104364254B (zh) | 作为β‑内酰胺酶抑制剂的杂二环化合物 | |
| JP5752114B2 (ja) | チオフェン誘導体 | |
| US10030044B2 (en) | Nucleotides for the treatment of liver cancer | |
| CN106795199B (zh) | 作为hiv逆转录酶抑制剂的4’-取代的核苷衍生物 | |
| ES2911449T3 (es) | Dihidropirimidinoisoquinolinonas y sus composiciones farmacéuticas para el tratamiento de la esclerosis múltiple | |
| BR112018067392A2 (pt) | inibidores de ligação entre proteínas wdr5 | |
| BR112019013017A2 (pt) | compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos | |
| CN107074827B (zh) | 普拉二烯内酯吡啶化合物和使用方法 | |
| CN107849071A (zh) | 抗病毒的β氨基酸酯膦酰二胺化合物 | |
| BR112021007044B1 (pt) | Compostos moduladores de hemoglobina, suas composições e seus usos | |
| BR112013013127B1 (pt) | Processo para a preparação de derivados de morfolinil antraciclina, compostos derivados de morfolinil antraciclina e composição farmacêutica compreendendo estes compostos | |
| CN110403933A (zh) | 二氢青蒿素衍生物在制备抗肿瘤药物中的应用 | |
| AU2015243437A1 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| BR112019010924B1 (pt) | Compostos heterociclicos tetraciclicos uteis como inibidores de hiv integrase, sais farmaceuticamente aceitaveis dos mesmos, composures farmaceuticas e usos dos referidos compostos | |
| CN113912663B (zh) | 白桦脂酸衍生物，其制备方法、药物组合物和应用 | |
| CN108623576A (zh) | 用于抑制激酶活性的吲唑类化合物及其组合物及应用 | |
| CN110448551A (zh) | 二氢青蒿素衍生物在制备抗血管生成药物中的应用 | |
| BR112018009995B1 (pt) | Forma cristalina, composição farmacêutica, e, uso da forma cristalina | |
| CN110496121A (zh) | 二氢青蒿素衍生物在制备抗利什曼原虫的药物中的应用 | |
| JP2021506948A (ja) | Ｓｇｌｔ阻害剤及びその応用 | |
| EP3934757B1 (en) | 2'3'-cyclic dinucleotides and prodrugs thereof | |
| CN112979654A (zh) | 杂芳基稠环化合物、其制备方法及应用 | |
| JP2019522059A (ja) | Ｓ１ｐ１アゴニスト及びその応用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191105 |
|
| RJ01 | Rejection of invention patent application after publication |